Acura Pharmaceuticals Inc., a specialty pharmaceutical company innovating abuse deterrent drugs, announced in a press release receipt from the United States Patent and Trademark Office (USPTO) of a Notice of Allowance for a non-provisional patent application related to the abuse deterrent LIMITX Technology platform. A US patent relating to this Notice of Allowance will be granted by the USPTO after the Company pays the required fees.When issued, this will be the first US patent directed at products developed with the LIMITX Technology.
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITX, AVERSION and IMPEDE Technologies. LIMITX contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested.
Source: AG-IP News
